» Articles » PMID: 1331239

Sequence Motifs Important for Peptide Binding to the Human MHC Class I Molecule, HLA-A2

Overview
Journal J Immunol
Date 1992 Dec 1
PMID 1331239
Citations 82
Authors
Affiliations
Soon will be listed here.
Abstract

Previous studies have indicated that most HLA-A2-binding peptides are 9 amino acid (aa) residues long, with a Leu at position 2 (P2), and a Val or Leu at P9. We compared the binding properties of different peptides by measuring the rate of dissociation of beta 2-microglobulin from peptide-specific HLA-A2 complexes. The simplest peptide that we identified that could form HLA-A2 complexes had the sequence (in single letter aa code) GLFGGGGGV, indicating that three nonglycine aa are sufficient for binding to HLA-A2. To determine whether most nonapeptides that contained Leu at P2 and Val or Leu at P9 could bind to HLA-A2, we tested the binding of nonapeptides selected from published HIV and melanoma protein sequences, and found that six of seven tested formed stable HLA-A2 complexes. We identified an optimal antigenic undecapeptide from the cytomegalovirus gB protein that could form stable HLA-A2 complexes that contained apparent anchor residues at P2 and P11 (sequence FIAGN-SAYEYV), indicating that the spacing between anchor residues can be somewhat variable. Finally, we tested the importance of every aa in the influenza A matrix peptide 58-66 (sequence GILGFVFTL) for binding to HLA-A2, by using Ala-substituted and Lys-substituted peptides. We found that multiple positions were important for stable binding, including P2, P3, P5-P7, and P9. We conclude that the P2 and P9 anchor residues are of prime importance for peptide binding to HLA-A2. However, other peptide side chains (especially at P3) contribute to the stability of the interaction. In certain cases, the optimal length for peptide binding can be longer than 9 residues.

Citing Articles

Thioamide Analogues of MHC I Antigen Peptides.

Gibadullin R, Morris R, Niu J, Sidney J, Sette A, Gellman S J Am Chem Soc. 2023; 145(47):25559-25569.

PMID: 37968794 PMC: 10782604. DOI: 10.1021/jacs.3c05300.


Cross-Activation of Regulatory T Cells by Self Antigens Limits Self-Reactive and Activated CD8 T Cell Responses.

Cho E, Han S, Eom H, Lee S, Han C, Singh R Int J Mol Sci. 2023; 24(18).

PMID: 37761976 PMC: 10530955. DOI: 10.3390/ijms241813672.


Molecular mimicry and cancer vaccine development.

Tagliamonte M, Cavalluzzo B, Mauriello A, Ragone C, Buonaguro F, Tornesello M Mol Cancer. 2023; 22(1):75.

PMID: 37101139 PMC: 10131527. DOI: 10.1186/s12943-023-01776-0.


Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.

Baleeiro R, Chard Dunmall L, Liu P, Lu S, Lone Y, Lemoine N Front Immunol. 2022; 13:902709.

PMID: 35720289 PMC: 9204602. DOI: 10.3389/fimmu.2022.902709.


Opening opportunities for K determination and screening of MHC peptide complexes.

Kopicki J, Saikia A, Niebling S, Gunther C, Anjanappa R, Garcia-Alai M Commun Biol. 2022; 5(1):488.

PMID: 35606511 PMC: 9127112. DOI: 10.1038/s42003-022-03366-0.